Find comprehensive information on Metastatic Cholangiocarcinoma, including clinical documentation, ICD-10 codes C22.1, C78.7, and C79.51, medical coding guidelines, staging, treatment options, and prognosis. Learn about diagnostic criteria, biliary tract cancer, liver metastasis, and palliative care considerations for advanced cholangiocarcinoma. This resource provides essential information for healthcare professionals, coders, and patients seeking to understand this complex diagnosis.
Also known as
Malignant neoplasm of intrahepatic bile ducts
Cancer originating in the bile ducts within the liver, often metastasizing.
Malignant neoplasm of extrahepatic bile ducts
Cancer originating in bile ducts outside the liver, which can spread.
Secondary malignant neoplasm of liver and intrahepatic bile ducts
Cancer that has spread to the liver and bile ducts within it.
Secondary malignant neoplasm of other specified sites
Cancer that has spread to a specific site not listed elsewhere, potentially bile ducts.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the cholangiocarcinoma primary?
When to use each related code
| Description |
|---|
| Metastatic Cholangiocarcinoma |
| Localized Cholangiocarcinoma |
| Gallbladder Cancer |
Insufficient documentation of the primary origin site for metastatic cholangiocarcinoma leading to inaccurate coding (C22.1 vs. C78.7).
Incorrect sequencing of primary and metastatic codes (C22.1 and C78.7) impacting reimbursement and data analysis.
Lack of clear histology documentation (intrahepatic, extrahepatic) for metastatic cholangiocarcinoma impacting accurate code assignment (C22.0, C22.1, C24.0).
Patient presents with signs and symptoms suggestive of metastatic cholangiocarcinoma. The patient reports experiencing symptoms including jaundice, pruritus, abdominal pain, weight loss, and fatigue. Physical examination reveals palpable hepatomegaly and possible lymphadenopathy. Laboratory findings demonstrate elevated bilirubin, alkaline phosphatase, and CA 19-9 levels. Imaging studies, including abdominal ultrasound, CT scan of the abdomen and pelvis, and MRI with MRCP, demonstrate findings consistent with cholangiocarcinoma with evidence of metastatic disease to the liver, lymph nodes, or peritoneum. Biopsy confirmed the diagnosis of adenocarcinoma consistent with cholangiocarcinoma. The patient's case was discussed at multidisciplinary tumor board. Considering the patient's performance status and extent of metastatic disease, treatment options including chemotherapy, palliative care, and clinical trials were discussed. The patient opted to begin systemic chemotherapy with gemcitabine and cisplatin. Prognosis and potential treatment-related side effects were reviewed with the patient. Follow-up appointments were scheduled to monitor treatment response and manage any adverse events. The patient was provided with resources for supportive care and symptom management. Diagnosis codes for metastatic cholangiocarcinoma (C22.1), biliary obstruction (R17), and malignant ascites (R18.0) were considered. ICD-10-CM codes and appropriate medical billing codes were assigned.